

Resource Summary Report

Generated by [NIF](#) on Sep 22, 2026

PaTu 8988s

RRID:CVCL_1846

Type: Cell Line

Proper Citation

RRID:CVCL_1846

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1846

Proper Citation: RRID:CVCL_1846

Description: Cell line PaTu 8988s is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Pancreatic adenocarcinoma

Defining Citation: [PMID:1348891](#), [PMID:8194712](#), [PMID:11416159](#), [PMID:11668190](#), [PMID:15126341](#), [PMID:15688027](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:25167228](#), [PMID:25485619](#), [PMID:26216984](#), [PMID:26589293](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31395879](#)

Comments: Caution: TP53 mutation indicated incorrectly as being at p.Cys176Ser (c.451C>T) in PubMed=8194712., Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: PaTu 8988s

Synonyms: PA-TU-8988S, PaTu8988s, PaTu8988S, PATU8988S, PaTu 8988 S, PaTu-8988s, PATU-8988S, PATU-S, PA-TU S

Cross References: BTO:BTO_0005879, CLO:CLO_0008383, EFO:EFO_0006730, CLDB:cl3861, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, BioGRID_ORCS_Cell_line:258, BioSample:SAMN10987622, cancercellines:CVCL_1846, Cell_Model_Passport:SIDM00452, Cosmic:873007, Cosmic:2046530, Cosmic:2434103,

DepMap:ACH-000022, DSMZ:ACC-204, DSMZCellDive:ACC-204, EGA:EGAS00001000610, GEO:GSM887503, GEO:GSM888585, IARC_TP53:2967, IARC_TP53:30144, LiGeA:CCLE_100, LINCS_LDP:LCL-1745, Pharmacodb:PATU8988S_1237_2019, Progenetix:CVCL_1846, Wikidata:Q54938329

ID: CVCL_1846

Record Creation Time: 20220427T221412+0000

Record Last Update: 20260920T005415+0000

Ratings and Alerts

No rating or validation information has been found for PaTu 8988s.

No alerts have been found for PaTu 8988s.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 19 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Yang J, et al. (2026) A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(12), 2479.

Gong D, et al. (2026) GLIS3 marks a neural-like progenitor cell state that drives metastasis in pancreatic ductal adenocarcinoma. Cell reports, 45(5), 117314.

Woo SM, et al. (2026) Inhibiting Fatty Acid Oxidation Reverses Autophagy-Mediated Acquired Chemotherapy Resistance in Pancreatic Ductal Adenocarcinoma. Cancer research, 86(13), 3194.

Murr J, et al. (2026) The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma. MedComm, 7(6), e70794.

Rolver MG, et al. (2025) Tumor microenvironment acidosis favors pancreatic cancer stem cell properties and in vivo metastasis. iScience, 28(3), 111956.

Zhao B, et al. (2025) PLK1 blockade enhances the anti-tumor effect of MAPK inhibition in pancreatic ductal adenocarcinoma. Cell reports, 44(4), 115541.

Gaspar M, et al. (2025) An affinity-modulated T cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited cytokine release. *Journal for immunotherapy of cancer*, 13(8).

Wittenzellner K, et al. (2025) Label-free single-cell phenotyping to determine tumor cell heterogeneity in pancreatic cancer in real time. *JCI insight*, 10(13).

Cunniff PJ, et al. (2025) KLF5 enables dichotomous lineage programs in pancreatic cancer via the AAA+ ATPase coactivators RUVBL1 and RUVBL2. *Nature communications*, 16(1), 9996.

Gong D, et al. (2025) Integrated spatial morpho-transcriptomics predicts functional traits in pancreatic cancer. *Science advances*, 11(42), eadx0632.

Barrett AM, et al. (2024) Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancers. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(23), 5413.

Li TJ, et al. (2023) Deubiquitinating PABPC1 by USP10 upregulates CLK2 translation to promote tumor progression in pancreatic ductal adenocarcinoma. *Cancer letters*, 576, 216411.

Lier S, et al. (2022) A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer. *Bioorganic chemistry*, 119, 105505.

Heid I, et al. (2022) Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma. *Cancer & metabolism*, 10(1), 24.

Konno H, et al. (2022) ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell-mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models. *Cancer research communications*, 2(9), 937.

Dorsch M, et al. (2021) Statins affect cancer cell plasticity with distinct consequences for tumor progression and metastasis. *Cell reports*, 37(8), 110056.

Banh RS, et al. (2020) Neurons Release Serine to Support mRNA Translation in Pancreatic Cancer. *Cell*, 183(5), 1202.

Bian Y, et al. (2020) Robust, reproducible and quantitative analysis of thousands of proteomes by micro-flow LC-MS/MS. *Nature communications*, 11(1), 157.

Somerville TD, et al. (2020) Squamous trans-differentiation of pancreatic cancer cells promotes stromal inflammation. *eLife*, 9.